Skip to main content
. Author manuscript; available in PMC: 2013 Nov 18.
Published in final edited form as: Tetrahedron. 2012 Nov 18;68(46):9307–9343. doi: 10.1016/j.tet.2011.12.070

Figure 1.

Figure 1

Currently approved marine-derived pharmaceuticals: ω-conotoxin MVIIA (Prialt®, 1), Et-743 (Yondelis®, 2), halichondrin B (3), and eribulin mesylate (Halaven®, 4).